Phase 1b Study of VERVE-201 for Refractory Hyperlipidemia
This study is testing a new treatment called VERVE-201 for people with refractory hyperlipidemia (very high cholesterol and triglycerides that haven't responded to other treatments). VERVE-201 is given as an intravenous (IV) infusion and uses a special technology to help lower your cholesterol and triglycerides. The main goal of this study is to see how safe VERVE-201 is and to understand its effects on your body. You may be able to join if you are between 18 and 70 years old and have refractory hypercholesterolemia or hypertriglyceridemia. We are looking for 36 participants in total. The current recruitment status is unclear.
- Study design
- This is an open-label, Phase 1b study, meaning both you and the study team will know you are receiving VERVE-201. It will involve a single dose of VERVE-201 and plans to enroll 36 participants.
- What's involved
- Not specified in the trial record.
- Compensation
- Not stated in the trial record.
- Follow-up
- You will be followed for up to 365 days after receiving the treatment to monitor for side effects.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
Phase 1b Study of VERVE-201 in Patients With Refractory Hyperlipidemia
At a glance
Conditions
NCT06451770
Where you'd take part
This study runs at 16 sites. They're the same protocol — you choose where, and that choice sets who your contact draft is addressed to.
Clinical Study Center
Clearwater, Floridano site contact published
Recruiting
Clinical Study Center
Miami Lakes, Floridano site contact published
Recruiting
Clinical Study Center
Port Orange, Floridano site contact published
Recruiting
Clinical Study Center
New York, New Yorkno site contact published
Recruiting
Clinical Study Center
Adelaide, Australiano site contact published
Recruiting
Clinical Study Center
Melbourne, Australiano site contact published
Recruiting
Clinical Study Center
Chicoutimi, Canadano site contact published
Recruiting
Clinical Study Center
Montreal, Canadano site contact published
Recruiting
Sites open and close at different times, so the status above is per site — it can differ from the study's overall status.
Study leadership
- Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 8 AM - 8 PM Eastern time (UTC/GMT - 5 hours, EST) · STUDY_DIRECTOR · Eli Lilly and Company
Who to contact
Opens a ready-to-send draft in your own email app — review before sending.
Want this trial checked against your situation?
Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.
Inclusion
Exclusion
What this trial measures
- Incidence of treatment-emergent adverse events (TEAEs) and serious adverse events (SAEs)Up to Day 365